Next Phase Newsletter

A U.S.-headquartered multinational life sciences corporation develops, manufactures, and sells reagents, instruments, and provides services for the research, diagnostic, and bioprocessing markets. The firm is actively seeking opportunities aligned with its current pipeline and business, such as life science tools and services, diagnostics, spatial biology, and tech-bio. The firm primarily focuses on mergers and acquisitions, but equity investments are also possible. For equity investments, the sweet spot is around Series A and the firm prefers co-investment opportunities and may seek board or observer seats on a case-by-case basis. The firm is primarily interested in opportunities based in the U.S. and Europe. 
 
The firm is focused on tools and services, diagnostics, spatial biology, and tech-bio, such as platforms that enhance biopharma R&D and academic research. Technologies or products with strong strategic alignment to the corporation are preferred. The firm prioritizes companies that have a working prototype and ideally are already on the market, generating revenue. However, for equity investments, earlier-stage disruptive technologies may also be considered. 
 
The firm does not have specific requirements regarding a company’s founding team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm invests primarily in very early-stage companies, from pre-seed to seed stages. The firm’s average check size ranges from $250,000 to $500,000. While the firm is focused on the US, particularly in the West Coast, it remains open to global opportunities. The firm is flexible in both lending and co-investing and may seek an observer seat on a case-by-case basis. The firm plays an active role in supporting its portfolio companies, assisting them with concept validation, clinical trials, and navigating reimbursement and regulatory pathways. The firm also provides resources to help companies gather data and evidence for their minimum viable products. 
 
The firm is interested in opportunities across digital therapeutics, diagnostics, and medical devices. Some key indication areas of interest include cardiovascular, metabolic, diabetes, nephropathy, and women’s health. The firm typically focuses on less traditional pharma products, such as compounds and cell-based therapies. The firm prefers to engage with companies at an early stage and will consider those with at least a minimum viable product. 
 
The firm does not have specific requirements for a company’s founding team. However, the firm prefers companies based in the U.S. or those with incentives to relocate to the U.S. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global corporation and integrated business enterprise is interested in expanding the healthcare business and increasing its presence in the US. The firm seeks to make engage with early and mid-stage healthcare companies through strategic investment, partnerships, and more. The firm is open to global opportunities. 
 
Within life sciences and healthcare sectors, the firm is most interested in medical devices, diagnostics, digital health, and healthcare services. Within medtech, the firm focuses on surgical applications, respiratory/anesthesia, radiology, cardiology, etc. In digital health, technologies addressing areas such as virtual care providers, wellness management, etc. that could benefit the aging population are of interest. The firm is can partner with companies across a wide stage of development, from companies still developing a prototype to those who are already on the market. The firm does not invest in biotech or pharmaceutical companies. 
 
The firm has no specific company or management team requirements. The firm is interested in companies who are looking to enter the Asian market, and can help support the companies in navigating regulatory hurdles by leveraging their own regulatory team. The firm can act as a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A boutique venture capital firm manages an evergreen USD fund. The fund focuses on healthcare industry, generally participating in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $3-5M. The firm is open to both leading and co-investing. The firm is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad. 
 
The firm is most interested in biopharma, biotechnology, medical devices, artificial intelligence. Within medtech, the firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy. 
 
The firm is in search of ambitious companies with strong, experienced management teams. The firm takes a hands-on approach to portfolio companies and can work with incomplete teams. The firm can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the US is dedicated to advancing healthier outcomes for all by partnering with technology-powered innovators. The team consists of industry-seasoned leaders with deep health-tech experience. The firm will invest in Seed – Series B rounds, with a sweet spot for Series A. The firm makes initial equity investments of $3M-$10M and typically leads rounds. The firm will invest globally. 
 
The firm invests in healthcare software, services, and solutions based digital health companies. 
 
The firm has no strict team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A private investment vehicle established recently and headquartered in Asia is mainly interested in investing in global healthcare companies, co-investing in Pre-Seed up to Series A rounds. Currently, they have five portfolio companies spanning biotech, digital health, and medical devices. Initial check size is flexible, but the firm will allocate up to USD $400k up to Seed rounds and USD $1-2M up to Series A. 
 
The firm is open to biotech, first-in-class drugs, medical devices, digital health, and diagnostics. Though indication and technology-agnostic, next generation and innovative technologies are of interest. 
 
The firm does not have strict company or management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.